Free tool
FAERS Monitor: Calquence
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210259 or its brand name (Calquence, Acalabrutinib). Reports on generic versions are filed under their own applications.
Reports
12,744
Serious
10,675
84% of reports
Hospitalization
3,481
Death reported
2,699
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death2,186
- fatigue725
- headache657
- product dose omission issue522
- diarrhoea443
- fall395
- dyspnoea352
- contusion351
- pneumonia337
- malignant neoplasm progression325
- asthenia314
- pain302
- off label use289
- atrial fibrillation288
- nausea283
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 44 |
| 2018 | 193 |
| 2019 | 198 |
| 2020 | 588 |
| 2021 | 1,080 |
| 2022 | 1,443 |
| 2023 | 2,240 |
| 2024 | 2,719 |
| 2025 | 2,330 |
| 2026 | 1,908 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,415 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contusionSignal | 351 | 6.0 | 5.4 | 1,471 |
| malignant neoplasm progressionSignal | 325 | 5.3 | 4.7 | 1,116 |
| atrial fibrillationSignal | 288 | 4.9 | 4.4 | 889 |
| deathSignal | 2,186 | 4.2 | 4.0 | 5,531 |
| product dose omission issueSignal | 522 | 2.9 | 2.7 | 671 |
| fall | 395 | 2.0 | 1.8 | 187 |
| headache | 657 | 1.7 | 1.6 | 208 |
| pneumonia | 337 | 1.7 | 1.5 | 102 |
| fatigue | 725 | 1.5 | 1.4 | 141 |
| asthenia | 314 | 1.4 | 1.2 | 33 |
| diarrhoea | 443 | 1.1 | 1.0 | 7 |
| dyspnoea | 352 | 1.0 | 0.9 | 0 |
| pain | 302 | 0.8 | 0.7 | 13 |
| nausea | 283 | 0.6 | 0.5 | 83 |
| off label use | 289 | 0.5 | 0.5 | 114 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.